Comparing the utility of FDG PET-CT and contrast-enhanced CT in patients with oesophagogastric adenocarcinoma treated with neoadjuvant chemotherapy - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Evaluating the Effectiveness of FDG PET-CT Versus Contrast-Enhanced CT in Oesophagogastric Adenocarcinoma Patients Undergoing Neoadjuvant Chemotherapy

  • By

  • J. L. Moore

  • M. Arora

  • C. Sit

  • R. Rahman

  • M. Green

  • H. Deere

  • J. Lagergren

  • S. Chicklore

  • F. Chinaka

  • N. Maisey

  • S. Ngan

  • A. Sita-Lumsden

  • A. Qureshi

  • K. Owczarczyk

  • W. R. C. Knight

  • M. Kelly

  • C. R. Baker

  • J. A. Gossage

  • M. Subesinghe

  • A. R. Davies

  • September 17, 2026

Share

  • 1

    Neoadjuvant chemotherapy improves survival in oesophagogastric adenocarcinoma patients and is standard care in Western institutions.

  • 2

    International guidelines recommend FDG PET-CT after contrast-enhanced CT to identify occult metastatic disease before surgery.

  • 3

    CECT remains the most frequently used imaging technique for treatment-response assessment due to its low cost and availability.

  • 4

    The study aims to compare the accuracy of CECT and FDG PET-CT in predicting tumour invasion depth and nodal disease post-NACT.

  • 5

    There is no consensus on the optimal imaging modality for predicting pathological stage and treatment response in these patients.

Original Source(s)

Comparing the utility of FDG PET-CT and contrast-enhanced CT in patients with oesophagogastric adenocarcinoma treated with neoadjuvant chemotherapy

  • by J. L. Moore, M. Arora, C. Sit, R. Rahman, M. Green, H. Deere, J. Lagergren, S. Chicklore, F. Chinaka, N. Maisey, S. Ngan, A. Sita-Lumsden, A. Qureshi, K. Owczarczyk, W. R. C. Knight, M. Kelly, C. R. Baker, J. A. Gossage, M. Subesinghe, A. R. Davies

  • September 17, 2026

Related Content

Correction to: HLA Class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC

Quantitative stability of MGMT promoter methylation in recurrent glioma and implications for temozolomide rechallenge

Safety-Oriented Benchmarking of Large Language Models in Risk-Based Management of Abnormal Cervical Screening Results: Scenario-Based Benchmark Study